EUVIMEDEUVIMED entdecken
Crossref

Protein SUMOylation confers sorafenib resistance in human hepatocellular carcinoma via the induction of PKM2-mediated glycolysis

Hongchao Yuan, Yuanjun Lu, Zhuofeng Jiang, Yau-Tuen Chan, Junyu Wu, Zixin Feng, Lin Xu, Qiucheng Li, Pengde Lu, Chun-Fung Kwok, Tung-Leong Fong, Qinguo Huang und 4 weitere

Drug Resistance Updates · 2026-09 · 88 · 101451

DOI: 10.1016/j.drup.2026.101451 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-09. Verfasst von Hongchao Yuan und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 3 Sassoon Road, Pokfulam, Hong Kong. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 59 Literaturangaben. Gefördert von: University Grants Committee Research Grants Council, Innovation and Technology Fund, Health and Medical Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sorafenib resistance remains a major challenge in the treatment of hepatocellular carcinoma (HCC). Through an in vivo CRISPR/Cas9 screen, we identified protein SUMOylation as a key pathway enriched in sorafenib-resistant HCC tumors. SUMO1 expression was significantly upregulated in resistant tumors and cell lines, and its modulation directly influenced sorafenib sensitivity both in vitro and in vivo. Proteomic analysis revealed that SUMO1 overexpression enhanced glycolysis, and metabolic assays confirmed increased extracellular acidification rate (ECAR) and decreased oxygen consumption rate (OCR) in SUMO1-high cells. We further identified PKM2 as a key SUMOylation target, mediated by the E3 ligase TRIM28. The SUMOylation of PKM2 increased its enzymatic activity, promoted aerobic glycolysis, and conferred sorafenib resistance. The inhibition of PKM2 with Compound 3k reversed glycolytic flux and restored sorafenib sensitivity. Clinically, SUMOylated PKM2 was highly expressed in HCC tumors and was associated with the expression of markers of glycolysis and sorafenib resistance in HCC. Our study revealed a novel SUMO1-PKM2 axis that drives glycolysis and sorafenib resistance in HCC, suggesting a potential therapeutic target for overcoming drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibCarcinoma, HepatocellularLiver NeoplasmsDrug Resistance, NeoplasmCarrier ProteinsThyroid HormonesMembrane ProteinsSUMO-1 ProteinAntineoplastic AgentsHumansGlycolysisSumoylationThyroid Hormone-Binding ProteinsAnimalsCell Line, TumorGene Expression Regulation, NeoplasticMice

Stichwörter der Autor:innen

GlycolysisHepatocellular carcinomaPKM2SUMO1Sorafenib resistance

Substanzen

SorafenibThyroid Hormone-Binding ProteinsCarrier ProteinsThyroid HormonesMembrane ProteinsSUMO-1 ProteinAntineoplastic AgentsSUMO1 protein, human

Autor:innen und Institutionen

  • School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 3 Sassoon Road, Pokfulam, Hong Kong.
  • School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 3 Sassoon Road, Pokfulam, Hong Kong; Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Cen…
  • School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 3 Sassoon Road, Pokfulam, Hong Kong; Laboratory for Synthetic Chemistry and Chemical Biology Limited, Hong Kong Science Park, Hong Kong.
  • School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 3 Sassoon Road, Pokfulam, Hong Kong; Department of Neurosurgery, The Second Affiliated Hospital, Shantou University Medical College, Shan…
  • School of Pharmacy, Shandong Second Medical University, Weifang, Shandong, China.
  • Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA. Electronic address: chenz@stjohns.edu.

Förderung

  • University Grants Committee Research Grants Council
  • Innovation and Technology Fund
  • Health and Medical Research Fund

Zitieren

APA

Yuan, H., Lu, Y., Jiang, Z., Chan, Y. T., Wu, J., Feng, Z., Xu, L., Li, Q., Lu, P., Kwok, C. F., Fong, T. L., Huang, Q., Wei, L., Feng, Y., Chen, Z. S., & Wang, N. (2026). Protein SUMOylation confers sorafenib resistance in human hepatocellular carcinoma via the induction of PKM2-mediated glycolysis. Drug Resistance Updates, 88, 101451. https://doi.org/10.1016/j.drup.2026.101451

Vancouver

Yuan H, Lu Y, Jiang Z, Chan YT, Wu J, Feng Z, et al. Protein SUMOylation confers sorafenib resistance in human hepatocellular carcinoma via the induction of PKM2-mediated glycolysis. Drug Resistance Updates. 2026;88:101451. doi:10.1016/j.drup.2026.101451

BibTeX
@article{Yuan2026,
  author = {Yuan, Hongchao and Lu, Yuanjun and Jiang, Zhuofeng and Chan, Yau-Tuen and Wu, Junyu and Feng, Zixin and Xu, Lin and Li, Qiucheng and Lu, Pengde and Kwok, Chun-Fung and Fong, Tung-Leong and Huang, Qinguo and Wei, Liuya and Feng, Yibin and Chen, Zhe-Sheng and Wang, Ning},
  title = {Protein SUMOylation confers sorafenib resistance in human hepatocellular carcinoma via the induction of PKM2-mediated glycolysis},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {88},
  pages = {101451},
  doi = {10.1016/j.drup.2026.101451}
}
Kostenlos starten →